Free Trial
→ The Trump Dump is starting; Get out of stocks now? (From Paradigm Press) (Ad)
NASDAQ:XCUR

Exicure 6/6/2024 Earnings Report

Exicure logo
$10.50 -0.23 (-2.14%)
Closing price 03:59 PM Eastern
Extended Trading
$10.86 +0.36 (+3.43%)
As of 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Earnings History

Exicure EPS Results

Actual EPS
-$0.13
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Exicure Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Exicure Announcement Details

Quarter
Date
6/6/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Exicure's next earnings date is estimated for Wednesday, June 4, 2025, based on past reporting schedules.

Conference Call Resources

Exicure Earnings Headlines

Short Interest in Exicure, Inc. (NASDAQ:XCUR) Declines By 19.8%
May 4 at 2:25 AM | americanbankingnews.com
Why Exicure Inc. (XCUR) Soared on Monday
April 22, 2025 | msn.com
Your Wealth is Being Erased – Save It Before It’s Gone Forever
What If America's Gold Reserves Are a Lie? For decades, the U.S. government has claimed to have thousands of tons of gold locked away in Fort Knox. But there hasn't been an independent audit in over 50 years—and now, both Elon Musk and former Congressman Ron Paul are demanding answers.
May 6, 2025 | Hamilton Gold Group (Ad)
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma
April 14, 2025 | businesswire.com
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in ...
April 11, 2025 | gurufocus.com
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)
April 11, 2025 | investing.com
See More Exicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Exicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exicure and other key companies, straight to your email.

About Exicure

Exicure (NASDAQ:XCUR), an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

View Exicure Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles